AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22488662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohorts 1 + 2 (n = 68) among infants >90 days of age at diagnosis
Number of subjects: 209
Study 22488662 — intervention group
Group type: COMPARATOR
Intervention: Cohort 3 (n = 141) among infants >90 days of age at diagnosis
Number of subjects: 209
Study 22488662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohorts 1 + 2 (n = 68)
Number of subjects: 209
Study 22488662 — intervention group
Group type: COMPARATOR
Intervention: Cohort 3 (n = 141)
Number of subjects: 209
Study 20007756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (CS) 135 mg three times daily for 8 weeks
Number of subjects: 62
Study 20007756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 20007756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (CS)
Number of subjects: 62
Study 18347912 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise
Number of subjects: 242
Study 18347912 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Number of subjects: 242
Study 18347912 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study 15881483 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried r-hFSH (300 IU)
Number of subjects: 39
Study 15881483 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid r-hFSH (300 IU)
Number of subjects: 39
Study 12605350 — intervention group
Group type: EXPERIMENTAL
Intervention: Agnus castus (AC: 120 ‐ 480 mg/die) for 14 days
Number of subjects: 20
Study 10529325 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 1265
Study 10529325 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1265
Study 9101801 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate necrectomy (within the first 3 days post-trauma)
Number of subjects: 66
Study 9101801 — intervention group
Group type: COMPARATOR
Intervention: Early necrectomy (from the fourth post-traumatic day)
Number of subjects: 66
Study 1854374 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.75g/kg
Number of subjects: 3
Study 1854374 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.25g/kg
Number of subjects: 3
Study 1854374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 6151504 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1-8 mg)
Number of subjects: 20
Study 6151504 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (0.1-0.8 mg)
Number of subjects: 20
Study 6151504 — intervention group
Group type: EXPERIMENTAL
Intervention: Single i.v. Propranolol (8 mg)
Number of subjects: 20
Study 6151504 — intervention group
Group type: EXPERIMENTAL
Intervention: Single i.v. Pindolol (0.8 mg)
Number of subjects: 20
Study 30707882 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-made pressure-resistant cap cotton cover
Number of subjects: 50
Study 30707882 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing with traditional hydrocolloid dressings
Number of subjects: 50
Study 29089093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglion plexus ablation (n = 101)
Number of subjects: 240
Study 29089093 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 100)
Number of subjects: 240
Study 29089093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglion plexus ablation
Number of subjects: 240
Study 29089093 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study 27448832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus Autofluorescence (FAF) images
Number of subjects: 2202
Study 27448832 — intervention group
Group type: COMPARATOR
Intervention: Color photographs
Number of subjects: 2202
Study 24231555 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-sprint training (RST) 2 d/wk
Number of subjects: 20
Study 24231555 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RST and squat resistance training with superimposed vibrations (RS+ST) 1 d/wk
Number of subjects: 20
Study 22414094 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt suture needles
Number of subjects: 300
Study 22414094 — intervention group
Group type: COMPARATOR
Intervention: Sharp suture needles
Number of subjects: 300
Study 20190601 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (treatment L)
Number of subjects: 15
Study 20190601 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment C)
Number of subjects: 15
Study 18471410 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet plus alpha-keto acid
Number of subjects: 89
Study 18471410 — intervention group
Group type: COMPARATOR
Intervention: Routine-protein diet
Number of subjects: 89
Study 18471410 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 89
Study 16274095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3431
Study 11827919 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (warfarin plus aspirin)
Number of subjects: 5059
Study 11827919 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 5059
Study 10406248 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.01 mg/kg, maximum 1.0 mg)
Number of subjects: 29
Study 10406248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous normal saline)
Number of subjects: 29
Study 7555258 — intervention group
Group type: EXPERIMENTAL
Intervention: oral low-dose acyclovir (600-800 mg per day)
Number of subjects: 66
Study 7555258 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 66
Study 1701507 — intervention group
Group type: EXPERIMENTAL
Intervention: polyvinylpyrrolidone‐iodine (Betaisodona)
Number of subjects: 150
Study 1701507 — intervention group
Group type: EXPERIMENTAL
Intervention: exogenous interferon alpha with polyvinylpyrrolidone‐iodo‐drops or trifluorothymidine‐drops
Number of subjects: 150
Study 1701507 — intervention group
Group type: COMPARATOR
Intervention: vasoconstrictor
Number of subjects: 150
Study 1701507 — intervention group
Group type: EXPERIMENTAL
Intervention: topical corticosteroids in combination with antibiotics
Number of subjects: 150
Study 7004478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganda 1.02 (guanethidine 1% and adrenaline 0.2% mixture)
Number of subjects: 77
Study 7004478 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline 1% (Simplene)
Number of subjects: 77
Study 7004478 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 1% (Sno-Pilo)
Number of subjects: 77
Study 31631361 — intervention group
Group type: EXPERIMENTAL
Intervention: Three fractional ablative CO2 laser treatments at 8‐week intervals
Number of subjects: 19
Study 31631361 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated areas)
Number of subjects: 19
Study 31495347 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% RPS
Number of subjects: 360
Study 31495347 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% RPS
Number of subjects: 360
Study 31495347 — intervention group
Group type: COMPARATOR
Intervention: 0% RPS (control)
Number of subjects: 360
Study 27922901 — intervention group
Group type: EXPERIMENTAL
Intervention: TeamSTEPPS training using simulation
Number of subjects: 201
Study 25009161 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) 2.5‐20 mg/d
Number of subjects: 293
Study 25009161 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic (CNV)
Number of subjects: 293
Study 25009161 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 293
Study 23720078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg.kg-1)
Number of subjects: 90
Study 23720078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg.kg-1)
Number of subjects: 90
Study 23720078 — intervention group
Group type: COMPARATOR
Intervention: Control group (physiologic iv)
Number of subjects: 90
Study 21630032 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (200 mg twice daily)
Number of subjects: 107
Study 21630032 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (1 g twice daily)
Number of subjects: 107
Study 21630032 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study 17224758 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% without BAC
Number of subjects: 690
Study 17224758 — intervention group
Group type: COMPARATOR
Intervention: Travoprost 0.004% with BAC
Number of subjects: 690
Study 15153205 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 microg.kg(‐1) before propofol 3 mg.kg(‐1)
Number of subjects: 40
Study 15153205 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 3 microg.kg(‐1) before propofol 3 mg.kg(‐1)
Number of subjects: 40
Study 11599644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 9572229 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg every 4 hours for three doses with or without oxytocin)
Number of subjects: 250
Study 9572229 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic saline infusion and oxytocin
Number of subjects: 250
Study 9572229 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 250
Study 9572229 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic saline infusion
Number of subjects: 250
Study 7759204 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrusion procedure
Number of subjects: 35
Study 7759204 — intervention group
Group type: COMPARATOR
Intervention: Eversion procedures
Number of subjects: 35
Study 2568016 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (specific dosage and duration not available)
Number of subjects: 0
Study 2568016 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (specific details not available)
Number of subjects: 0
Study 2568016 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (specific details not available)
Number of subjects: 0
Study 2568016 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy (specific details not available)
Number of subjects: 0
Study 2568016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of drugs (specific details not available)
Number of subjects: 0
Study 53429 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly buffered acetylsalicylate
Number of subjects: 28
Study 31453920 — intervention group
Group type: COMPARATOR
Intervention: Traditional King-Devick test (control group)
Number of subjects: 96
Study 31453920 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized King-Devick test
Number of subjects: 96
Study 31101700 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg three times a day
Number of subjects: 668
Study 31101700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide inhaler 20 μg two puffs three times a day
Number of subjects: 668
Study 31101700 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey 30 mg (a spoonful) three times a day
Number of subjects: 668
Study 31101700 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 668
Study 28605109 — intervention group
Group type: EXPERIMENTAL
Intervention: Valnoctamide 1500 mg/d (n=71)
Number of subjects: 173
Study 28605109 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/d (n=32)
Number of subjects: 173
Study 28605109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=70)
Number of subjects: 173
Study 25470423 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shockwave therapy (LI-ESWT)
Number of subjects: 112
Study 25470423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 25470423 — intervention group
Group type: EXPERIMENTAL
Intervention: Active placebo group (previously placebo)
Number of subjects: 112
Study 23718084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal modulated currents applied to the vegetative nods on the neck
Number of subjects: 0
Study 23718084 — intervention group
Group type: COMPARATOR
Intervention: Beginning of the school year clinical conditions
Number of subjects: 0
Study 21136213 — intervention group
Group type: EXPERIMENTAL
Intervention: Navcap (V 25 mg/m2 on d1 and d8 and C 825 mg/m2 bid D1‐14 q3w) for 4 cycles followed by Navcap (A)
Number of subjects: 106
Study 21136213 — intervention group
Group type: COMPARATOR
Intervention: Weekly docetaxel (25 mg/m²/week) for 12 cycles (B)
Number of subjects: 106
Study 18327566 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency-based chondroplasty (RFC)
Number of subjects: 60
Study 18327566 — intervention group
Group type: COMPARATOR
Intervention: Mechanical shaver debridement (MSD)
Number of subjects: 60
Study 17519305 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d for 3 months
Number of subjects: 0
Study 17519305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15122531 — intervention group
Group type: EXPERIMENTAL
Intervention: First-void urine specimens
Number of subjects: 0
Study 15122531 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral swabs
Number of subjects: 0
Study 15122531 — intervention group
Group type: EXPERIMENTAL
Intervention: Semen specimens
Number of subjects: 0
Study 15122531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three specimens (first-void urine, urethral swabs, semen)
Number of subjects: 0
Study 11580908 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 40
Study 11580908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9566830 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (450 mg, 150 mg three times per day)
Number of subjects: 200
Study 9566830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9566830 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 200
Study 8169656 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained‐release ferrous sulfate (150 mg) daily for 14 weeks
Number of subjects: 87
Study 8169656 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets daily for 14 weeks
Number of subjects: 87
Study 3414573 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon filled with 400 mL water
Number of subjects: 8
Study 3414573 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon filled with 600 mL water
Number of subjects: 8
Study 3414573 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon filled with 800 mL water
Number of subjects: 8
Study 3414573 — intervention group
Group type: COMPARATOR
Intervention: Balloon filled with 0 mL water
Number of subjects: 8
Study 3414573 — intervention group
Group type: COMPARATOR
Intervention: Balloon filled with 200 mL water
Number of subjects: 8
Study 28332246 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced stop light diet (eSLD)
Number of subjects: 150
Study 28332246 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet (CD)
Number of subjects: 150
Study 27029284 — intervention group
Group type: EXPERIMENTAL
Intervention: One-pill DAPT
Number of subjects: 965
Study 27029284 — intervention group
Group type: COMPARATOR
Intervention: Two-pill DAPT
Number of subjects: 965
Study 24967362 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 677TT genotype
Number of subjects: 233
Study 24967362 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIC 675T carriers
Number of subjects: 233
Study 24967362 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncurrent smokers
Number of subjects: 233
Study 24967362 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients positive to anti-cyclic citrullinated peptide
Number of subjects: 233
Study 24967362 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients positive to antinuclear antibodies
Number of subjects: 233
Study 24967362 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher health assessment questionnaire score
Number of subjects: 233
Study 24967362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug users
Number of subjects: 233
Study 24967362 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration route
Number of subjects: 233
Study 22643944 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (cefazolin at 1.0 g i.v.) only at anesthetic induction
Number of subjects: 630
Study 22643944 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (cefazolin at 1.0 g i.v. at anesthetic induction and oral amoxicillin at 1 g every 12 hours for 7 days)
Number of subjects: 630
Study 22643944 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 630
Study 21677119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil
Number of subjects: 0
Study 18482233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propacetamol (40 mg.kg(‐1) via 15 min infusion)
Number of subjects: 26
Study 18482233 — intervention group
Group type: COMPARATOR
Intervention: Rectal paracetamol (20 mg.kg(‐1) every 6 h)
Number of subjects: 26
Study 15876311 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen allergoid
Number of subjects: 154
Study 11996473 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF regimen (cyclophosphamide 100 mg/m2 p.o. on days 1 to 14, methotrexate 40 mg/m2 i.v. on days 1 and 8, 5‐fluorouracil 600 mg/ml i.v. on days 1 and 8; cycles q. 28 days)
Number of subjects: 254
Study 10076611 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy with patch closure (CEAP)
Number of subjects: 310
Study 10076611 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid eversion endarterectomy and reimplantation (CEER)
Number of subjects: 310
Study 7723713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided liver biopsy using the 0.95 mm cutting biopsy cannula
Number of subjects: 160
Study 7723713 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous liver biopsy with the 1.4 mm Menghini needle
Number of subjects: 160
Study 1669520 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 22071
Study 1669520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 6986897 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 73
Study 6986897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 30269149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical interleukin‐2 (IL‐2) instillations with a marker lesion
Number of subjects: 28
Study 30269149 — intervention group
Group type: COMPARATOR
Intervention: Intravesical interleukin‐2 (IL‐2) instillations without a marker lesion
Number of subjects: 28
Study 28686775 — intervention group
Group type: EXPERIMENTAL
Intervention: A/BPO gel 0.3%/2.5%
Number of subjects: 217
Study 28686775 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 217
Study 28686775 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 217
Study 26000685 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial ultrasound-guided stellate ganglion block with 4 mL of 0.375% levobupivacaine (group S)
Number of subjects: 46
Study 26000685 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C) without SGB
Number of subjects: 46
Study 23597267 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry powder
Number of subjects: 20
Study 23597267 — intervention group
Group type: COMPARATOR
Intervention: Strawberry-flavoured placebo preparations
Number of subjects: 20
Study 21266447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary plant-derived polysaccharide supplement (AC)
Number of subjects: 69
Study 21266447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 19189909 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body examination by primary care clinician
Number of subjects: 0
Study 19189909 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-examination for skin cancer
Number of subjects: 0
Study 19189909 — intervention group
Group type: COMPARATOR
Intervention: Screening for skin cancer
Number of subjects: 0
Study 17174508 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin tablet formulation 1
Number of subjects: 0
Study 17174508 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin tablet formulation 2
Number of subjects: 0
Study 15098801 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron solution (4 mg)
Number of subjects: 16
Study 15098801 — intervention group
Group type: EXPERIMENTAL
Intervention: Extemporaneous ondansetron capsule formulation (4 mg)
Number of subjects: 16
Study 15098801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 16
Study 11774070 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (1 l/h of a 6% carbohydrate beverage)
Number of subjects: 98
Study 11774070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 98
Study 11774070 — intervention group
Group type: EXPERIMENTAL
Intervention: Runners reporting URTI
Number of subjects: 98
Study 11774070 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects combined
Number of subjects: 98
Study 11774070 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion
Number of subjects: 98
Study 9704868 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 81
Study 9704868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 8556752 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-containing chewing gum
Number of subjects: 13
Study 8556752 — intervention group
Group type: COMPARATOR
Intervention: Control (no gum)
Number of subjects: 13
Study 2493523 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin ointment (NTG)
Number of subjects: 0
Study 2493523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 631110 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity arm cranking exercise
Number of subjects: 17
Study 631110 — intervention group
Group type: COMPARATOR
Intervention: High intensity bench stepping with arms at sides
Number of subjects: 17
Study 31166415 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide cement (CHC)
Number of subjects: 36
Study 31166415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 36